PsyBio Therapeutics Corp. (PSYBF)
OTCMKTS · Delayed Price · Currency is USD
0.0050
+0.0049 (4,900.01%)
Oct 17, 2025, 4:00 PM EDT
PsyBio Therapeutics Company Description
PsyBio Therapeutics Corp., a biotechnology company, engages in the research, development, and commercialization of psychedelic-inspired regulated medicines for the treatment of mental health and other disorders in the United States.
PsyBio Therapeutics Corp. was formerly known as Leo Acquisitions Corp. and changed its name to PsyBio Therapeutics Corp. in January 2021.
The company was incorporated in 2009 and is headquartered in Denver, Colorado.
PsyBio Therapeutics Corp.
| Country | Canada |
| Founded | 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Evan Levine |
Contact Details
Address: 1624 Washington Street Denver, British Columbia 80203 United States | |
| Phone | 513 449 9585 |
| Website | psybiolife.com |
Stock Details
| Ticker Symbol | PSYBF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | CA6936971044 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Evan Mike Levine | Co-Founder, Chief Executive Officer and Chairman |
| Dr. Michael Spigarelli M.B.A., M.B.E., M.D., Ph.D. | Chief Scientific Officer and Chief Medical Officer |
| Ross Carmel | Chief Legal Officer and Director |
| Noah Isidore Davis | Secretary and Director |
| Andrew Jones | Inventor and Chairman of Scientific Advisory Board |